Compare Iris Energy Limited (IREN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs Neurocrine Biosciences Inc — how do they compare? Iris Energy Limited trades at $36.6 (market cap $14.07B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Iris Energy Limited and Neurocrine Biosciences Inc are close in size by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IREN | NBIX | |
|---|---|---|
Market Cap | $14.07B | $14.36B |
Volume | 54,492,460 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $76.41 | $185.50 |
52-Week Low | $29.31 | $123.10 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $16.02B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN trades at $38.69, down 6.27% today, amid a bearish technical trend and recent earnings misses. The company is aggressively pivoting from Bitcoin mining to AI infrastructure, securing multi-billion dollar contracts, but faces ballooning losses with a net income margin of -99.38% in 2026. Analyst consensus remains strongly bullish with a $81 price target, highlighting long-term revenue potential from AI demand, yet near-term execution and profitability challenges weigh on investor sentiment.
Outlook hinges on successful execution of AI expansion and cost management; opportunities include massive contracted revenue growth, but risks involve high capital burn, intense competition, and persistent negative earnings. The stock offers significant upside if targets are met, but volatility is expected amid transformative shifts.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
